Registry Study on AL Amyloidosis to Understand Disease Progression and Treatment Effects

What this Trial Is About

This research aims to create a large registry of patients diagnosed with AL amyloidosis to better understand the natural course of this condition in everyday medical settings. By collecting data at diagnosis and throughout follow-up, the study seeks to describe how the disease progresses and to develop reliable models for predicting outcomes, treatment responses, and relapses at any stage of the illness. Participants in this observational study contribute information collected during their routine clinical care without receiving experimental treatments. The registry includes data from patients who have not yet received treatment for AL amyloidosis, with retrospective data also collected where available. Participants are followed over time at the participating centers as part of their usual care. During the study, researchers gather clinical information at diagnosis and during follow-up visits. Outcome measures focus on building and maintaining the registry over a five-year period. The study does not assign specific treatments but observes patients in real-world settings to understand the impact of therapies and progression patterns. Participation may last several years as data accumulates to support future research and improve patient care.

A Registry of AL Amyloidosis (ReAL)